Beneficial effect of probiotics supplements in reflux esophagitis treated with esomeprazole: A randomized controlled trial

• Published in: World journal of gastroenterology : WJG Vol. 25; no. 17; pp. 2110 - 2121
• Main Authors: Sun, Qing-Hua, Wang, Hong-Yan, Sun, Shi-Dong, Zhang, Xin, Zhang, Han
• Format: Journal Article
• Language: English
• Published: United States Baishideng Publishing Group Inc 07.05.2019
• Subjects: Adolescent; Adult; Aged; Bacillus subtilis; Body Mass Index; Clinical Trials Study; Dietary Supplements; Endoscopy; Enterococcus faecium; Esomeprazole - administration & dosage; Esophagitis, Peptic - therapy; Female; Gastrointestinal Microbiome; Humans; Male; Middle Aged; Probiotics - administration & dosage; Proportional Hazards Models; Proton Pump Inhibitors - administration & dosage; Recurrence; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome; Young Adult; Probiotics; Proton pump inhibitors; Small intestinal bacterial overgrowth; Relapse; Reflux esophagitis
• ISSN: 1007-9327; 2219-2840; 2219-2840
• DOI: 10.3748/wjg.v25.i17.2110

Reflux esophagitis (RE) is a common digestive disorder, and its frequent recurrences cause significant physical pain and are financially burdensome to patients. However, studies on the natural history of treated RE are few. Although proton pump inhibitors (PPIs) as the first-line treatment provide notable symptomatic relief, disordered gut microbiota has been observed among PPI users. Probiotics are commonly administered to patients to regulate the disordered intestinal flora. To evaluate the therapeutic effects in RE patients treated with a combination of esomeprazole and probiotics [ ( ) and ( )]. One hundred and thirty-four RE patients were randomized into two groups of 67 subjects each. The probiotics group was administered with esomeprazole 20 mg . and live combined and enteric-coated capsules 500 mg . for eight weeks; the placebo group was administered with esomeprazole 20 mg . and placebo for eight weeks. Subsequently, 12-wk follow-up was carried out on patients who achieved both endoscopic and clinical cure. Endoscopy, reflux diagnostic questionnaire (RDQ), gastrointestinal symptom rating scale (GSRS), and lactulose hydrogen breath test were performed to evaluate the therapeutic effects. A difference of < 0.05 was considered statistically significant. Sixty-six patients in the probiotics group and 64 patients in the placebo group completed the 8-wk treatment. The healing rate and RDQ score had no significant difference between the two groups ( > 0.05). However, the GSRS diarrhea syndrome score was decreased significantly in the probiotics group ( = 0.002), and the small intestinal bacterial overgrowth negative rate in the probiotics group was significantly higher than that in the placebo group ( = 0.002). Of 114 endoscopically and clinically cured patients, 96 completed the follow-up. The log-rank test showed that the time to relapse was shorter in the placebo group than in the probiotics group ( = 0.041). Furthermore, the therapy had a significant influence on relapse time, and the risk of relapse in the probiotics group was lower than that in the placebo group at any time point during the 12-wk follow-up (hazard ratio = 0.52, = 0.033). Esomeprazole combined with probiotics ( and ) have a beneficial effect on RE treatment and patient management.